Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. - Wikidata - awgldk - TriplyDB

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.

http://www.wikidata.org/entity/Q37063563

about

Radionuclide Methods in the Diagnosis of Sacroiliitis in Patients with Spondyloarthritis: An Update 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study The Role of Imaging in Diagnosing Axial Spondyloarthritis.

P2860

Q28078330-3AD3F44A-435C-425A-A756-9D4EABA16199 Q37494175-92E4A794-9824-4742-92FC-023CEA8B10D7 Q55119880-C5E7F86C-70EF-43E4-BCC1-7AEACDE689AF

P2860

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.

http://www.wikidata.org/entity/Q37063563

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@en

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@nl

type

label

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@en

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@nl

prefLabel

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@en

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@nl

P1433

Q37063563-76489BEE-EBBD-48BB-BE0D-02972C081F24

P1476

Q37063563-0FC6C43E-274F-47F8-BBCF-20665C1F7D0E

P2093

Q37063563-35F49975-4AF3-4AD4-A2D6-E60744F759ED

Q37063563-5D1B53E1-E9EE-4455-B5AA-16467ECC455A

Q37063563-66435D1C-A43E-4E06-8260-3C2BCE5BE15A

Q37063563-8BC9126C-013A-4CBA-877C-77BE1D7796BA

Q37063563-92E0F13B-EBF0-4272-AA95-DC6B45F18512

Q37063563-A041DA06-B36C-48C3-9878-F725E7A2AA15

Q37063563-B2ED54C6-EF02-47E1-B522-2AEA5FCD34D4

Q37063563-DDA27618-7157-4CE3-87D9-2391F892A012

P2860

Q37063563-02CD47F6-4A58-4FAC-9BAE-7CB376F51DC9

Q37063563-0466C7BF-FC78-471C-98B6-F627C691A32A

Q37063563-0743C916-856D-44C5-87A9-5ECF47F433A5

Q37063563-0D3E20FD-1AF8-45EA-8A6B-222ACE6398DC

Q37063563-0D5A0793-F04F-4B87-8CC6-FF9D4DC1B633

Q37063563-0E59F733-4375-45F3-BEC7-C5574B832500

Q37063563-11CD9086-D5C6-4F33-93B0-943E8F00EEB4

Q37063563-2E115792-B973-47EC-9734-685F8ABB2D86

Q37063563-32E65A8F-FE16-4611-BFAA-862DB0DE2BFE

Q37063563-3A306225-B90D-4DE4-BA34-5F60869225E5

P304

Q37063563-FCF8EDB0-C772-4A48-835C-001C9E2CB231

P31

Q37063563-DFA302E2-C652-45BE-91A1-A73431DCD756

P356

Q37063563-FF096B42-B192-4A44-850E-D059C30DC505

P433

Q37063563-D89F6519-70D1-4351-986F-C1B00F7F3AF1

P478

Q37063563-1E0FA7E6-95E7-4A05-9B9F-C3D00D803CF5

P577

Q37063563-7E404868-E11F-48D2-A9F3-91CDE7B689CF

P698

Q37063563-F5EDD910-0F3A-45A8-9874-C73ED6FDCFA2

P921

Q37063563-0D1C064D-DD43-491F-B3EC-AF0CC8AF49D8

Q37063563-93F6B5F2-C8C7-4FB6-ABE1-637942692677

P932

Q37063563-1A710C87-B05F-4F34-AFA8-957A941A2711

P356

RMDOPEN-2016-000265

P1433

P1476

Scintigraphic detection of TNF ...... thritis and spondyloarthritis.

@en

P2093

Bieke Lambert

http://www.w3.org/2001/XMLSchema#string

Dirk Elewaut

http://www.w3.org/2001/XMLSchema#string

Filip De Vos

http://www.w3.org/2001/XMLSchema#string

Filip Van den Bosch

http://www.w3.org/2001/XMLSchema#string

Gaëlle Varkas

http://www.w3.org/2001/XMLSchema#string

Lennart Jans

http://www.w3.org/2001/XMLSchema#string

Liesbet Van Praet

http://www.w3.org/2001/XMLSchema#string

Philippe Carron

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis.

Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.

Certolizumab pegol for the treatment of Crohn's disease.

P304

e000265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2016-000265

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27403334

http://www.w3.org/2001/XMLSchema#string

P921

P932

4932275

http://www.w3.org/2001/XMLSchema#string